NASDAQ : VRXA
VERAXA Biotech AG — Key statistics
Healthcare · Biotechnology · Germany
Last price 1.16 USD (Oct 30, 2026, 2:22 PM EDT) · Market cap 164.03M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 148.12M |
| Enterprise Value | 147.53M |
Dates
| Measure | Value |
|---|
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 141.41M |
| Shares Outstanding | 141.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 41.51% |
| Owned by Institutions (%) | 0.46% |
| Float | 36.79M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5,456.62 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5,436.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.44 |
| Quick Ratio | 0.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18,644.03 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -871.42% |
| Return on Assets (ROA) | -49.99% |
| Return on Invested Capital (ROIC) | -478.61% |
| Return on Capital Employed (ROCE) | -89.23% |
| Weighted Average Cost of Capital (WACC) | 5.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -495,117 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -90.21% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 6.92 |
| Relative Strength Index (RSI) | 41.47 |
| Average Volume (20 Days) | 307,442 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 107,383 |
| Short Previous Month | 235,019 |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.47 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 29,543 |
| Gross Profit | 19,498 |
| Operating Income | -83.51M |
| Pretax Income | -84.50M |
| Net Income | -84.01M |
| EBITDA | -81.02M |
| EBIT | -83.51M |
| Loss Per Share | -$5.80 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.04M |
| Total Debt | 1.44M |
| Net Cash | 596,937 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -19.88M |
| Book Value Per Share | -1.35 |
| Working Capital | -4.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.08M |
| Capital Expenditures | -533,445 |
| Depreciation & Amortization | 2.41M |
| Net Borrowing | 1.02M |
| Free Cash Flow | -12.62M |
| FCF Per Share | -$0.09 |
Margins
| Measure | Value |
|---|
| Gross Margin | 66.00% |
| Operating Margin | -282,661.28% |
| Pretax Margin | -286,033.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -554.05% |
| FCF Yield | -7.83% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.78 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |